Navigation Links
China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results

HAIKOU CITY, China, May 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2012.

First Quarter 2012 Highlights

  • Revenue was $16.1 million, compared to $18.1 million in the prior year period;
  • Gross profit was $5.3 million, compared to $6.9 million in the prior year period;
  • Operating income was $3.4 million, compared to $5.3 million in the prior year period;
  • Net income was $2.8 million, or $0.06 per basic and diluted share, compared to $5.3 million in the prior year period, or $0.12 per basic and diluted share;
  • "This year we expect to see many new Healthcare Reform policy implementations, most of which are centered around the theme of price control. At the same time we are seeing cost of materials (such as raw chemical materials, APIs, packaging materials as well as logistic costs) rising fast. The Chinese pharmaceutical industry is therefore facing tremendous operating pressure due to falling top line and rising cost of goods sold." Ms. Zhilin Li, China Pharma's Chairman and CEO continued, "With respect to the first quarter, new government pricing policies as well as the general uncertain atmosphere of the industry negatively impacted our short-term results. But we expect gross margin and revenue to benefit from new product launches in the months and quarters ahead."

    First Quarter of FY2012 Results of OperationsRevenues for the quarter ended March 31, 2012 were $16.1 million, a decrease of $2.0 million, or 11% from $18.1 million for the quarter ended March 31, 2011. Decline in our total revenue was due to the sales decrease in our four major product categories.Most of the decline in our total revenue was from our "Other's" category where sales fell by 37% to $2.0 million from $3.1 million for the same period last year. Sales in the Anti-Viro Infection & Respiratory category fell by 4% to $6.8 million from $7.1 million in the prior year period. The "Digestive" category sales revenues edged lower by 2% to $2.5 million from $2.6 million in the same period prior year. Sales of CNS Cerebral & Cardio Vascular products fell by 11% to $4.8 million from $5.4 million in the first quarter of 2011.

    Gross profit for the three months ended March 31, 2012 was $5.30 million, which was approximately 23% lower compared to $6.87 million for the quarter ended March 31, 2011. Our gross margin for the first quarter of 2012 was 33%, compared to 38% in the corresponding quarter of 2011. We are seeing pricing pressure on many of our products, particularly digestive drugs, although the pressure is not uniform across product lines. Pricing pressure has become more evident over the past few quarters as the Chinese government healthcare reform is having a stronger impact on all pharmaceutical products, especially the products listed on National Essential Drug List. We expect current challenging pricing environment to persist for some time.

    In terms of our gross margins by major categories, CNS Cerebral & Cardio Vascular category margin was 39.4%, lower compared to the first quarter 2011 gross margin of 45.3%. Gross margin for our Anti-Viro/Infection & Respiratory category decreased to 25.4% from 27.5% in the period one year ago. Gross margin for our Digestive Diseases category decreased to 35.7% from 48.4%, in the period one year ago. Gross margin for our Other category fell to 40.0% from 44.9% a year ago.

    Selling, general and administrative expenses in the first quarter of 2012 were $1.57 million, compared to $1.52 million, in the same period of 2011.  The decrease in general and administrative expenses along with the revenue did not completely offset the increasing selling expenses mainly due to higher labor cost.

    For the quarter ended March 31, 2012, the Company's bad debt expense was $320,098, compared to $9,248 in the same period of 2011. The increase was mainly due to the higher percentage of the older accounts receivables.

    Operating income was $3.4 million in the first quarter of 2012, down 36% from $5.3 million in the first quarter of 2011. Operating income was lower mainly due to lower revenue and lower gross margins and higher operating expenses in the current period compared to the corresponding quarter one year ago. 

    For the quarter ended March 31, 2012, the Company paid income tax at a rate of approximately 15%.  Income tax expense for the first quarter of 2012 was $0.53 million, compared to $0.85 million for the same period last year. The Company obtained "National High-Tech Enterprise" status from the PRC government in the fourth quarter of 2010.  With this designation, the Company is entitled to a preferential tax rate of 15% for three years from 2011 to 2013, which is notably lower than the statutory income tax rate of 25%.

    Net income for the first quarter of 2012 was $2.8 million, or $0.06 per basic and diluted share, compared to $5.1 million, or $0.12 per basic and diluted share, in the first quarter of 2011. The decrease of net income from the period a year ago is mainly due to the decrease in sales revenue, falling gross margins and higher operating expenses. Our net income for the first quarter of 2011 also included a positive effect of $0.68 million of derivative gains.

    Financial ConditionAs of March 31, 2012, the Company had cash and cash equivalents of $3.3 million compared to $4.1 million as of December 31, 2011.

    Working capital increased to $99.9 million at March 31, 2012 from $96.8 million at December 31, 2011.  The current ratio decreased to 6.8 times at March 31, 2012 from 8.0 times at December 31, 2011.

    Accounts receivable balance rose to $73.5 million at the end of the first quarter of 2012 from $69.7 million at the end of 2011. The Company's management team continues to be sharply focused on improving accounts receivable collection and expects to make progress in the quarters to come.

    For the three months ended March 31, 2012, cash flow from operating activities was $0.12 million, as compared to $1.39 million in the period a year ago.

    Pipeline UpdateAs of March 31, 2012, China Pharma had various pipeline drugs in different stages of active development.  Some of these are highlighted below:

  • The Company originally submitted application for production approval of Candesartan, a front-line drug therapy developed for the treatment of hypertension, in 2010. The Company received request for additional procedures in the fourth quarter of 2011 and has since completed all newly requested procedures. We now expect SFDA to give us the final production approval by mid-year 2012.
  • The Company completed clinical trials of Rosuvastatin, a generic form of Crestor, and is in the process of production approval process.
  • The Company completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic in September 2010.  We are currently conducting Phase II clinical trials for this drug.
  • The Company is developing a medicine for the treatment of coronary heart disease. This product comes with a patented TCM formula and we are currently conducting Phase III clinical trials for this drug. We anticipate the completion of the clinical work for this product by year end 2012.
  • Conference CallThe Company will hold a conference call at 8:30 am ET on May 15, 2012 to discuss first quarter 2012 results.  Listeners may access the call by dialing 1-866-519-4004 or 65-672-393-81 for international callers, Conference ID # 78450563. A webcast will also be available through CPHI's website at  A replay of the call will be accessible through May 22, 2012 by dialing 1-866-214-5335 or 61-282-355-000 for international callers, Conference ID # 78450563.

    About China Pharma Holdings, Inc. China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit The Company routinely posts updated information on its website.

    Safe Harbor Statement  Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

    China Pharma Holdings, Inc.
    Phone: +86-898-6681-1730 (China)

    4,050,854Banker's acceptances365,28583,512Trade accounts receivable, less allowance for doubtfulaccounts of $3,876,469 and $3,536,405, respectively73,546,11169,695,556Other receivables, less allowance for doubtfulaccounts of $41,106 and $38,921, respectively75,60455,039Advances to suppliers4,871,9285,778,841Inventory34,323,34530,378,658Deferred tax assets617,753566,226Total Current Assets117,119,832110,608,686Advances for purchases of property and equipment171,402170,323Advances for purchases of intangible assets37,212,57036,194,494Property and equipment, net of accumulated depreciation of$3,624,697 and $3,391,124, respectively6,170,7446,334,817Intangible assets, net of accumulated amortization of$3,213,631 and $3,041,804, respectively2,949,6253,082,671TOTAL ASSETS$ 163,624,173$ 156,390,991LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Trade accounts payable$
    3,112,385Accrued expenses145,212184,017Accrued taxes payable3,544,8783,082,353Other payables890,698784,697Advances from customers2,015,3801,784,474Other payables - related parties861,563899,314Short-term notes payable3,956,6423,931,745Total Current Liabilities17,268,24813,778,985Long-term deferred tax liability143,407128,909Total Liabilities17,411,65513,907,894Stockholders' Equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized;no shares issued or outstanding--Common stock, $0.001 par value; 95,000,000 shares authorized;43,529,557 shares and 43,529,557 shares outstanding, respectively

    43,53043,530Additional paid-in capital23,505,02223,448,534Retained earnings107,093,025104,286,666Accumulated other comprehensive income15,570,94114,704,367Total Stockholders' Equity146,212,518142,483,097TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 163,624,173$ 156,390,991 

     CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE INCOME(Unaudited)For the Three MonthsEnded March 31,20122011Revenue$ 16,086,731$ 18,119,557Cost of revenue10,782,38411,249,946Gross profit5,304,3476,869,611Operating expenses:Selling expenses894,060604,481General and administrative expenses676,402916,945Bad debt expense320,0989,428Total operating expenses1,890,5601,530,854Income from operations3,413,7875,338,757Other income (expense):Interest income6901,961Interest expense(77,537)(61,214)Derivative gain-677,498Net other income (expense)(76,847)618,245Income before income taxes3,336,9405,957,002Income tax expense(530,581)(853,380)Net income2,806,3595,103,622Other comprehensive income - foreign currencytranslation adjustment866,5741,138,038Comprehensive income$   3,672,933$   6,241,660Earnings per Share:Basic$
    .12 CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)For the Three MonthsEnded March 31,20122011Cash Flows from Operating Activities:Net income$2,806,359$5,103,622Depreciation and amortization365,223441,993Stock based compensation56,48941,898Bad debt expense320,0989,428Deferred income taxes(34,312)(1,414)Derivative gain-(677,498)Changes in assets and liabilities:Trade accounts receivable(5,154,644)(1,464,957)Other receivables(20,247)(72,955)Advances to suppliers944,949794,570Inventory(2,619,634)(2,525,349)Trade accounts payable2,725,945(1,261,422)Accrued expenses11,517194,444Accrued taxes payable443,684184,552Other payables54,33744,932Advances from customers219,942574,632Net Cash Provided by Operating Activities119,7061,386,476Cash Flows from Investing Activities:Net investment in banker's acceptances-(467,902)Advances for purchases of property and equipment and intangible assets(790,092)(848,378)Purchase of property and equipment(7,926)(60,949)Net Cash Used in Investing Activities(798,018)(1,377,229)Cash Flows from Financing Activity:Proceeds from related party loan-67,919Net Cash Provided by Financing Activity-67,919Effect of Exchange Rate Changes on Cash(52,736)34,393Net Increase in Cash and Cash Equivalents(731,048)111,559Cash and Cash Equivalents at Beginning of Period4,050,8543,692,086Cash and Cash Equivalents at End of Period$3,319,806$3,803,645Supplemental Cash Flow Information:Cash paid for interest$
    58,170Cash paid for income taxes274,587385,546Supplemental Noncash Investing and Financing Activities:Accounts payable for purchases of property and equipment

    $   144,057$   143,839Accounts receivable collected with banker's acceptances1,420,102-Inventory purchased with banker's acceptances1,138,429- 


    SOURCE China Pharma Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. China Biologic Products Reports Higher Results for the First Quarter 2012
    2. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
    3. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
    4. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
    5. CentraState and Freehold Radiology Group train physicians from China
    6. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
    7. Professor Vishnu Chaturvedi of New York, USA Gives a Lecture at West China Hospital of Sichuan University
    8. China Botanic Announces Results of Annual General Meeting
    9. China Shenghuo Pharmaceutical Reports Financial Results for the Full Year 2011
    10. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
    11. Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform
    Post Your Comments:
    (Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
    (Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
    (Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
    (Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
    (Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
    (Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
    Breaking Medicine News(10 mins):